No Prescription |
 |
 | ||
|
Theo Dur Theochron |
|
| ||
No Prescription » Prescription Drugs 16 » Theo Dur Theochron Theophylline is used to prevent and treat wheezing shortness of breath and difficulty breathing caused by asthma chronic bronchitis emphysema and other lung diseases. It relaxes and opens air passages in the lungs making it easier to breathe. Buy Theo Dur Theochron and other Prescription Drugs 16 products online at Medstore. 143
About Theo Dur Theochron: Product Type: Prescription Drugs 16 Theo-Dur ( Theochron Uniphyl Generic Theophylline ) Theo-Dur (Theochron Uniphyl Generic Theophylline) Theochron Uniphyl Generic Theophylline 300mg 100 tabs Theochron Uniphyl Generic Theophylline Theo-Dur
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
